Skip to main content
. 2019 Oct 15;19:90. doi: 10.1186/s12894-019-0530-0

Fig. 1.

Fig. 1

a-c Kaplan–Meier curves for all patients. a Recurrence free survival; b progression free survival; c Treatment failure free survival. Tumor recurrence, progression and treatment failure differ significantly between these groups. Comparing with epirubin or pirarubicin group, gemcitabine group showed obvious advantage in inhibiting tumor recurrence, progression and treatment failure